Davidson Kempner Capital Management’s Xilio Therapeutics XLO Stock Holding History
Bought
Maintained
Sold
Other funds holding XLO
AG
Davidson Kempner Capital Management's XLO Position: Q1 2022 in Review
Davidson Kempner Capital Management sold out of Xilio Therapeutics (XLO) in Q1 2022, closing a stake of 2,071 shares — an estimated $458K sold.
Davidson Kempner Capital Management first reported a position in XLO in Q4 2021 and held it in 1 quarter. The position peaked at $458K in Q4 2021. 41 funds tracked by Wall St. Rank hold XLO as of Q1 2022.
- Davidson Kempner Capital Management reported no remaining Xilio Therapeutics position as of Q1 2022 after selling out during the quarter.
- Davidson Kempner Capital Management sold 2,071 Xilio Therapeutics shares in Q1 2022, an estimated $458K.
- Davidson Kempner Capital Management first reported a position in Xilio Therapeutics in Q4 2021 and held it in 1 quarter.
- Davidson Kempner Capital Management's Xilio Therapeutics position peaked at $458K in Q4 2021.
- 41 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2022.
Based on Davidson Kempner Capital Management's 13F filing for Q1 2022, filed 16 May 2022.